The story mentions that Avastin is associated with serious side effects, such as high blood pressure and internal bleeding; however, it did not provide data on how many women in each treatment arm experienced these side effects. The story briefly mentioned the two trials, RIBBON-1 and AVADO, on which the FDA will base their decision whether to revoke approval of the Avastin. The story could have mentioned that both were double-blind, randomized, placebo-controlled trials and enrolled women with HER-2 neu negative tumors. It also would have been helpful if the reader knew that the women in the trials received another chemotherapy agent in combination with Avastin or a placebo. But a bigger issue is
Looming ruling on breast cancer drug splits patient advocates